Inventor · disambiguated record
Xiaofen Li
Also filed as: LI XIAOFEN
42 granted patents·21 pending applications·503 citations·filing 2002–2025
98Inventor score
Files withGILEAD SCIENCES INC19CV THERAPEUTICS INC14AMGEN INC9ELZEIN ELFATIH4CORKEY BRITTON KENNETH3
Top patents by PatentIndex Score
63 records- 0197US10988451B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2020·Granted Apr 27, 2021·10 cites·21 claims
- 0296US11643400B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2021·Granted May 9, 2023·4 cites·20 claims
- 0396US10703733B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2019·Granted Jul 7, 2020·12 cites·27 claims
- 0496US6825349B2A2B adenosine receptor antagonistsCV THERAPEUTICS INC·Filed 2002·Granted Nov 30, 2004·95 cites·31 claims
- 0595US7317017B2A2B adenosine receptor antagonistsCV THERAPEUTICS INC·Filed 2005·Granted Jan 8, 2008·22 cites·15 claims
- 0694US9371329B2Fused heterocyclic compounds as ion channel modulatorsCORKEY BRITTON·Filed 2014·Granted Jun 21, 2016·26 cites·2 claims
- 0794US8952034B2Fused heterocyclic compounds as ion channel modulatorsCORKEY BRITTON·Filed 2010·Granted Feb 10, 2015·29 cites·18 claims
- 0894US8586732B2Fused heterocyclic compounds as ion channel modulatorsCORKEY BRITTON KENNETH·Filed 2012·Granted Nov 19, 2013·29 cites·35 claims
- 0994US6977300B2A2B adenosine receptor antagonistsCV THERAPEUTICS INC·Filed 2003·Granted Dec 20, 2005·69 cites·25 claims
- 1093US7741331B2A2B adenosine receptor antagonistsGILEAD PALO ALTO INC·Filed 2007·Granted Jun 22, 2010·16 cites·8 claims
- 1192US8697863B2Fused heterocyclic compounds as ion channel modulatorsGILEAD SCIENCES INC·Filed 2013·Granted Apr 15, 2014·13 cites·11 claims
- 1291US9676760B2Fused heterocyclic compounds as ion channel modulatorsGILEAD SCIENCES INC·Filed 2016·Granted Jun 13, 2017·7 cites·2 claims
- 1391US9598435B2Fused heterocyclic compounds as ion channel modulatorsGILEAD SCIENCES INC·Filed 2015·Granted Mar 21, 2017·9 cites·13 claims
- 1491US7125993B2A2B adenosine receptor antagonistsCV THERAPEUTICS INC·Filed 2003·Granted Oct 24, 2006·37 cites·47 claims
- 1590US9193694B2Fused heterocyclic compounds as ion channel modulatorsGILEAD SCIENCES INC·Filed 2013·Granted Nov 24, 2015·11 cites·11 claims
- 1690US7795269B2A2B adenosine receptor antagonistsGILEAD PALO ALTO INC·Filed 2007·Granted Sep 14, 2010·8 cites·14 claims
- 1789US8389500B2Fused heterocyclic compounds as ion channel modulatorsABELMAN MATTHEW·Filed 2009·Granted Mar 5, 2013·16 cites·24 claims
- 1887US7521554B2A2B adenosine receptor antagonistsCV THERAPEUTICS INC·Filed 2006·Granted Apr 21, 2009·7 cites·5 claims
- 1987US2025154116A1Mcl-1 inhibitorsGILEAD SCIENCES INC·Filed 2024·Application pending·0 cites
- 2086US7304070B2A2B adenosine receptor antagonistsCV THERAPEUTICS INC·Filed 2004·Granted Dec 4, 2007·23 cites·36 claims
- 2184US9403782B2Fused heterocyclic compounds as ion channel modulatorsGILEAD SCIENCES INC·Filed 2015·Granted Aug 2, 2016·4 cites·10 claims
- 2284US8324224B2A2B adenosine receptor antagonistsKALLA RAO·Filed 2011·Granted Dec 4, 2012·5 cites·8 claims
- 2383US8158810B2ALDH-2 inhibitors in the treatment of addictionZABLOCKI JEFF·Filed 2009·Granted Apr 17, 2012·7 cites·11 claims
- 2482US12162844B2MCL-1 inhibitorsGILEAD SCIENCES INC·Filed 2023·Granted Dec 10, 2024·0 cites·14 claims
- 2582US11040033B2Therapeutic heterocyclic compoundsGILEAD SCIENCES INC·Filed 2018·Granted Jun 22, 2021·1 cites·22 claims
- 2682US8962610B2Fused heterocyclic compounds as ion channel modulatorsCORKEY BRITTON KENNETH·Filed 2012·Granted Feb 24, 2015·6 cites·21 claims
- 2781US9115096B2Fused heterocyclic compounds as ion channel modulatorsCORKEY BRITTON KENNETH·Filed 2012·Granted Aug 25, 2015·5 cites·13 claims
- 2881US7381714B2A1 adenosine receptor agonistsCV THERAPEUTICS INC·Filed 2006·Granted Jun 3, 2008·4 cites·22 claims
- 2980US7105665B2A2B adenosine receptor antagonistsCV THERAPEUTICS INC·Filed 2004·Granted Sep 12, 2006·12 cites·33 claims
- 3077US7514417B2A1 adenosine receptor agonistsCV THERAPEUTICS INC·Filed 2006·Granted Apr 7, 2009·2 cites·23 claims
- 3176US2025304599A1Macrocyclic compounds and methods of useAMGEN INC·Filed 2024·Application pending·0 cites
- 3274US7696181B2Partial and full agonists of A1 adenosine receptorsCV THERAPEUTICS INC·Filed 2006·Granted Apr 13, 2010·1 cites·23 claims
- 3374US7488720B2A1 adenosine receptor agonistsCV THERAPEUTICS INC·Filed 2006·Granted Feb 10, 2009·1 cites·13 claims
- 3473US7144871B2Partial and full agonists of A1 adenosine receptorsCV THERAPEUTICS INC·Filed 2003·Granted Dec 5, 2006·5 cites·15 claims
- 3572US7449473B2Substituted pyrrolo[3,2-d]pyrimidin-2,4-diones as A2b adenosine receptor antagonistsCV THERAPEUTICS INC·Filed 2004·Granted Nov 11, 2008·5 cites·16 claims
- 3669US2025236631A1Macrocyclic compounds and methods of useAMGEN INC·Filed 2025·Application pending·0 cites
- 3767US7022681B2Partial and full agonists of A1 adenosine receptorsCV THERAPEUTICS INC·Filed 2003·Granted Apr 4, 2006·2 cites·23 claims
- 3865US12412680B2Composite superconducting tape, combination and preparation method thereof, and defect bypassing and joint connection methodUNIV SHANGHAI JIAOTONG·Filed 2023·Granted Sep 9, 2025·0 cites·10 claims
- 3963US11229638B2Therapeutic heterocyclic compoundsGILEAD SCIENCES INC·Filed 2018·Granted Jan 25, 2022·0 cites·7 claims
- 4063US2009137802A1A2b adenosine receptor antagonistsELZEIN ELFATIH·Filed 2009·Application pending·0 cites
- 4162US2013123280A1A2b adenosine receptor antagonistsGILEAD SCIENCES INC·Filed 2012·Application pending·0 cites
- 4260US2009156544A1A1 adenosine receptor agonistsELZEIN ELFATIH·Filed 2009·Application pending·0 cites
- 4360US2009137520A1A1 adenosine receptor agonistsELZEIN ELFATIH·Filed 2009·Application pending·0 cites
- 4459US2025163064A1Quinazoline compounds and uses thereof as inhibitors of mutant kras proteinsAMGEN INC·Filed 2023·Application pending·0 cites
- 4558US2011130362A1A2b adenosine receptor antagonistsGILEAD SCIENCES INC·Filed 2011·Application pending·0 cites
- 4658US2025179077A1Quinazoline compounds and uses thereof as inhibitors of mutant kras proteinsAMGEN INC·Filed 2023·Application pending·0 cites
- 4756US2010222300A1A2B Adenosine Receptor AntagonistsGILEAD PALO ALTO INC·Filed 2010·Application pending·0 cites
- 4855US2025034167A1Heterocyclic compounds and methods of useAMGEN INC·Filed 2022·Application pending·0 cites
- 4955US2025122222A1Heterocyclic compounds and methods of useAMGEN INC·Filed 2022·Application pending·0 cites
- 5054US2025059179A1Heterocyclic Compounds and Methods of UseAMGEN INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 63 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Xiaofen Li files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →